Who is the biggest winner of Fujian bidding scheme?

Source: on the last day of medical cloud information and sabilan 2014-10-08 September, Fujian Province finally released the implementation plan for 2014 centralized drug procurement of medical institutions in Fujian Province In the scheme, domestic drugs certified by FDA will be included in the first quality level, which is one of the highlights Although there are many domestic raw material enterprises certified by FDA, there are only a few preparation enterprises This means that some manufacturers with R & D advantages, such as Hengrui and other enterprises, will gain the advantage of bidding price If it's just "facing the scheme research scheme", you may think very rashly that there are several possibilities to gain the price advantage (only the comparative advantage) in Fujian bidding and become the winner in the market: 1) exclusive varieties; 2) individually priced varieties; 3) FDA certified varieties However, this is only a few price highlands left after the price is suppressed In addition to the price, the provincial catalogue and the catalogue of each city divided into districts are the fierce market access competition of each enterprise It should be noted that there are only 2655 varieties in the provincial catalogue, and each city divided into districts will further screen them within this range There's no problem with the provincial and municipal directories When you enter the bidding and online price negotiation link, you won the bid, but you dare not laugh Because there are hospitals that do bid next This is Fujian's characteristic You have to adapt What you may not expect is that the above enterprises occupying those high prices are not the biggest winners The last one is Fujian local enterprises Although there is no specific quantitative preferential policy like Chongqing double 50%, Fujian Province's care for local pharmaceutical enterprises is meticulous The difficulties of Fujian's drug bidding and purchase lie in: first, to enter the provincial and local level purchase catalogue, which is the major premise; second, to confirm the bid one by one in various cities and cities For foreign enterprises, the workload and difficulty can be imagined The local enterprises do not have these obstacles, which can be said to be a green light of policy, with a very obvious competitive advantage According to the document spirit of the notice of the people's Government of Fujian Province on twelve measures to speed up the development of the pharmaceutical industry, "drugs and medical devices produced in Fujian Province shall be included in the shortlist of centralized procurement in priority under the same conditions." The provincial drugs and medical devices that have won the bid will no longer be confirmed and will be directly purchased and used by medical institutions " On September 26, Fujian held a meeting to promote medical reform Relevant personnel of Fujian provincial drug centralized procurement leading group office made a speech at the meeting, and said in the speech of "precautions for work in all regions": each city divided into districts shall issue the implementation measures for drug centralized procurement in their own regions as soon as possible, and within the scope of provincial procurement catalogue, according to the types of common diseases, payment level of medical insurance, clinical medication habits and other situations in all regions, make sure To establish the directory of centralized drug procurement in the region In order to implement the requirements of the notice of the people's Government of Fujian Province on twelve measures to accelerate the development of the pharmaceutical industry, the varieties of drugs produced in the province that are included in the provincial procurement catalogue shall be protected as much as possible, and the products of the province in the same products shall be given priority At the same time, actively strive to include the drugs produced in the province into the national basic medical insurance drug catalog and the national basic drug catalog, and give priority to supplement and enter the provincial basic medical insurance drug catalog under the same conditions Class 3 and above chemicals, class 6 and above traditional Chinese medicine and biological products with new drug certificate produced by the province shall be included in the drug catalogue of basic medical insurance of the province in time according to the prescribed procedures For the provincial exclusive, local characteristics, key drug varieties, dosage forms and specifications that are not included in the national essential drug catalogue, they shall be included in the national essential drug provincial supplementary varieties catalogue preferentially under the same conditions Under the same conditions, the drugs produced in the province in the directory of basic medical insurance drugs are preferentially included in the new rural cooperative medical insurance reimbursement drug directory of the province Under the same conditions, drugs and medical devices produced in the province will be included in the shortlist of centralized procurement The provincial drugs and medical devices that have won the bid will not be confirmed and will be directly purchased and used by medical institutions The preferential policies of local enterprises are not only limited to entering the catalogue and avoiding the confirmation of standards In the use of medical institutions, the province has also made special care: 1) public medical institutions at all levels in the province should give priority to purchasing and using the drugs and medical devices produced in the province in the catalogue of centralized procurement; 2) For the newly approved provincial drugs and medical devices that have missed the provincial centralized purchase, if the price is not higher than the shortlist price of the same kind of products, they should be put into the provincial centralized purchase network of drugs and medical devices in time for medical institutions to choose to purchase; 3) for the medical treatment projects using the large-scale medical devices produced in the province, they should be listed in the medical insurance reimbursement project preferentially; 4) The medical institutions of the province should increase the proportion of purchasing drugs produced by the province, and include it into the objective management of the medical institutions 5) We will give full play to the guiding role of price policies and support pharmaceutical enterprises in the province in the production and supply of clinically necessary low-cost drugs Fujian's drug purchase idea is comprehensive, but it must not be confused by the low price theory, which is criticized by the public In addition to the price, the more challenging market access policy is the most difficult obstacle for most enterprises to overcome, while the local enterprises get the ticket given by the policy, and take the green direct bus to go away.